Key facts
- Owlstone Medical’s last known valuation is $273.7M (Mar 2025).
- It has raised $212.7M; the latest was Later Stage VC ($31.4M) in Mar 2025.
- Notable investors include Gates Foundation, Horizons Ventures, Ventura Capital, HSBC Global Custody Nominee (UK), Aviva Ventures — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Owlstone Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for Owlstone Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Owlstone Medical
Developer of a healthcare breathalyzer product designed to focus on non-invasive diagnostics for the early detection of disease and on precision medicine. The company is developing a biopsy product and a proprietary sample collection device that can take stable breath samples anywhere, enabling doctors to avail detection of diseases, including lung cancer, liver disease, digestive health, and respiratory disease.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2003
- Employees
- 174
- Website
- owlstonemedical.com/
- Ownership
- Privately Held (backing)
Owlstone Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Owlstone Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Owlstone Medical in its N-PORT filings yet. We sweep new filings monthly.